AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the IL-23 inhibitor Skyrizi (risankizumab) with Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen’s Stelara (ustekinumab) in patients with moderate-to-severe Crohn’s disease (CD) unresponsive to anti-TNF therapy. The blinded efficacy assessment revealed that Skyrizi achieved clinical and endoscopic remission rates of 59% and 32%, respectively, surpassing Stelara’s rates of 40% and 16%, and thus meeting the coprimary endpoints of the study.
Consistency in Safety Profile for Skyrizi
Skyrizi’s safety profile in this trial was found to be consistent with previous studies, providing confidence in its potential as a treatment option for patients with Crohn’s disease. This consistency is crucial for the drug’s global development and potential regulatory approvals.
Global Development Partnership
The global development of Skyrizi is being led by AbbVie in partnership with Boehringer Ingelheim (BI). This collaboration aims to leverage the strengths of both companies in advancing therapies for inflammatory bowel diseases, such as Crohn’s disease, which affects a significant patient population worldwide.-Fineline Info & Tech
